Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Yearbook of Dermatology and Dermatologic Surgery

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YDER.2011.01.027
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

  2009cited by this paper

• Construction of a management and prevention program for targeted therapy-induced hand-foot skin reaction

  2026cites this paper
• Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial

  2022cites this paper
• Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature

  2022influential citation
• Scrotal Erythema: First Sign of a Cutaneous Drug Reaction to Pazopanib

  2021cites this paper
• Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports

  2021cites this paper
• Nilotinib‐induced lichen planopilaris

  2021cites this paper
• Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

  2021influential citation
• An unusual case of progressive nodular histiocytosis

  2021cites this paper
• Side skin reactions of multikinase inhibitors in treatment of thyroid cancer

  2021influential citation
• Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib)

  2021cites this paper
• Cutaneous toxicities of targeted therapies in the treatment of hepatocellular carcinoma

  2020influential citation
• Sorafenib Induced Hand-Foot Skin Reaction at Low Dose

  2020cites this paper
• Sunitinib-induced pyoderma gangrenosum-like skin ulcer

  2020cites this paper
• Bone Marrow-Derived Stem Cells as a Cytotherapy for Sirolimus-Induced Periodontal Ligament and Alveolar Bone Injury in a Rat Model

  2019cites this paper
• Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin

  2018cites this paper
• Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female

  2018cites this paper
• Unusual and Interesting Adverse Cutaneous Drug Reactions

  2018cites this paper
• Intratumoral Predictive Markers in Metastatic Renal Cancer Patients

  2018cites this paper
• Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients

  2018cites this paper
• Associat ion of Toxicity of Sorafenib and Sunit inib for Human Kerat inocytes with Inhibit ion of Signal Transduct ion and Act ivator

  2018cites this paper
• An Update on Drug-induced Oral Reactions.

  2018cites this paper
• Correlation Between the Tyrozinkinazine Inhibitor Sunitinib - Dose, Schedule of Administration and Adverse Events

  2017cites this paper
• Cutaneous Reactions to Targeted Therapy.

  2017cites this paper
• Managing tyrosine kinase inhibitors side effects in thyroid cancer

  2017influential citation
• SORAFENIB INDUCED ACNEIFORM ERUPTIONS: A CASE REPORT

  2017cites this paper
• New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

  2017cites this paper
• CS2164, a novel multi‐target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti‐tumor potency

  2017cites this paper
• Sorafenib-asssociated hand-foot syndrome treated with topical calcipotriol

  2017cites this paper
• Gottron-Like Papules Induced by Sunitinib

  2017cites this paper
• Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer

  2017cites this paper
• A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17

  2017cites this paper
• Vandetanib-eluting Radiopaque Beads: In vivo Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization

  2017cites this paper
• Paradoxical exacerbation of chronic plaque psoriasis by sorafenib

  2016cites this paper
• Multikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management

  2016influential citation
• Stevens - Johnson Syndrome Induced by Sorafenib for Hepatocellular Carcinoma

  2016cites this paper
• Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib*

  2016cites this paper
• Selective use of sorafenib in the treatment of thyroid cancer

  2016cites this paper
• Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie

  2016cites this paper
• Drug-induced hair colour changes

  2016cites this paper
• Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer

  2016cites this paper
• Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients

  2016cites this paper
• Cutaneous complications of molecular targeted therapy used in oncology

  2016influential citation
• Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib

  2016cites this paper
• Strategies for Prevention and Treatment of Chemotherapy-Induced Hand-Foot- Skin-Reaction (HFSR)

  2016cites this paper
• Sorafenib for the treatment of thyroid cancer: an updated review

  2015cites this paper
• Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand–foot syndrome during chemotherapy: a meta‐analysis

  2015cites this paper
• Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

  2015cites this paper
• Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study

  2015cites this paper
• Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

  2015cites this paper
• Melanonychia and Blue lunulae with the Multikinase Inhibitor Sorafenib

  2015influential citation
• Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.

  2015cites this paper
• Interest of reflectance confocal microscopy for inflammatory oral mucosal diseases

  2015cites this paper
• Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib

  2015cites this paper
• The new therapeutical scenario of Hodgkin lymphoma.

  2015cites this paper
• Sunitinib‐induced pseudoporphyria

  2015cites this paper
• New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus*

  2015cites this paper
• Aktuelle Entwicklungen in der Prävention und Therapie des Hand- und Fußsyndroms

  2015cites this paper
• Preventative measures and prompt recognition are vital when managing dermatological toxicities associated with targeted cancer therapies

  2015cites this paper
• CRM1 Blockade by Selective Inhibitors of Nuclear Export (SINE) attenuates Kidney Cancer Growth

  2015cites this paper
• Fármacos antiangiogénicos y piel: efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab

  2014cites this paper
• Sorafenib and sunitinib: A dermatologist's perspective

  2014cites this paper
• Perforating folliculitis-like reaction related to sorafenib.

  2014cites this paper
• Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions

  2014cites this paper
• Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.

  2014influential citation
• The great mimickers of rosacea.

  2014cites this paper
• Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management

  2014influential citation
• The use of sunitinib in renal cell carcinoma: where are we now?

  2014cites this paper
• Association of Toxicity of Sorafenib and Sunitinib for Human Keratinocytes with Inhibition of Signal Transduction and Activator of Transcription 3 (STAT3)

  2014cites this paper
• Pain related to cancer treatments and diagnostic procedures: a no man's land?

  2014cites this paper
• Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor

  2014cites this paper
• Acne inversa‐like lesions associated with the multi‐kinase inhibitor sorafenib

  2014cites this paper
• Geographic tongue induced by angiogenesis inhibitors.

  2013cites this paper
• Risk Factor of the Hand/foot Skin Reaction Induced by Sorafenib in Patients with Advanced Hepatocellular Carcinoma

  2013cites this paper
• Efficacy and safety of targeted narrowband ultraviolet B therapy using a flat‐type fluorescent lamp for the treatment of palmoplantar pustulosis

  2013cites this paper
• Case of sunitinib‐induced Stevens–Johnson syndrome

  2013cites this paper
• Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors

  2013influential citation
• Vemurafenib-Induced Eccrine Squamous Syringometaplasia

  2013cites this paper
• EVUE GÉNÉRALE nomalies pigmentaires induites par les traitements nticancéreux . Deuxième partie : les thérapies iblées igmentary disorders induced by anticancer agents . Part II : Targeted therapies

  2013cites this paper
• Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma

  2013cites this paper
• Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch

  2013cites this paper
• Sunitinib‐induced scrotal cutaneous side‐effect

  2013cites this paper
• Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib

  2013cites this paper
• Skin Reactions Secondary to Anticancer Agents

  2013cites this paper
• A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib.

  2013cites this paper
• Mammalian target of rapamycin inhibitor-associated stomatitis.

  2013cites this paper
• Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

  2012cites this paper
• Concentration and volume effects in thermochemical ablation in vivo: Results in a porcine model

  2012cites this paper
• Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors

  2012influential citation
• Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.

  2012influential citation
• Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.

  2012cites this paper
• Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma

  2012cites this paper
• Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies

  2012cites this paper
• Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells

  2012cites this paper
• Cutaneous Reactions to Novel Therapeutics

  2012cites this paper
• large B-cell lymphoma of Waldeyer ’ s ring has distinct clinicopathologic features: a GELA study

  2012cites this paper
• Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts.

  2011cites this paper
• Häufige Haut-Nebenwirkungen von neuen onkologischen Medikamenten

  2011cites this paper
• [Dermatologic side effects induced by new angiogenesis inhibitors].

  2011influential citation
• Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib

  2011cites this paper
• Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long‐term use

  2011cites this paper